17 results
Thumbnail

D1.326 - Six Cases of Adult-Onset PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Cervical Adenopathy) Syndrome

Thumbnail

D1.327 - A Rare Primary Immunodeficency Hidden in Autoimmunity: Heterozygote CD3G variant in a 49-year-old Female Patient

Thumbnail

D1.332 - Hereditary Angioedema in Ukraine

Thumbnail

D1.333 - A Newly Identified POLE1 Deficiency (FILS Syndrome) Patient with Severe Immunodeficiency: Clinical Course and Treatment Approach

Thumbnail

D1.334 - A Novel Variant in ALPS Type V Due to CTLA-4 Deficiency: A Case Presenting with Cytopenia

Thumbnail

D1.335 - TeloNet is born; why immunologists should know about telomere disorders

Thumbnail

D1.336 - Sirolimus for the treatment of the Immunodeficiency Linked to PIK3CD (APDS1)

Thumbnail

D1.337 - Clinical features of patients submitted to immunoglobulin replacement therapy in an outpatient regimen at a tertiary hospital during 2024

Thumbnail

D3.364 - Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema

Thumbnail

D3.358 - The impact of limited access to On-Demand Treatment for Hereditary Angioedema on Quality of life: a comparison between two income settings

Thumbnail

D3.359 - Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment

Thumbnail

D3.362 - Use and safety of canakinumab during pregnancy

Thumbnail

D3.363 - Vitamin D3 deficiency promotes epithelial-to-mesenchymal transition and thus favours pulmonary fibrosis development in the murine model of hypersensitivity pneumonitis

Thumbnail

D3.365 - The role of anosmia in predicting biologic responsiveness for Chronic Rhinosinusitis with Nasal Polyposis

Thumbnail

D3.366 - Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria

Thumbnail

D3.367 - Mental health, sexual functionality, quality of life, and patient experiences with chronic rhinosinusitis with nasal polyps at UNIMEQ-ORL in Bogotá, Colombia, 2022-2024: a mixed-methods study

Thumbnail

D3.368 - Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year